Thomas Meier
Founder bij SANTHERA PHARMACEUTICALS HOLDING AG
Vermogen: 152 196 $ op 31-03-2024
Profiel
Dr. Thomas Meier is a Chairman at Santhera Pharmaceuticals Holding AG and a Managing Partner at Viopas Venture Consulting GmbH.
He is on the Board of Directors at Onconetix, Inc., Visgenx, Inc. and Novaremed AG.
Dr. Meier was previously employed as a Chief Executive Officer by MyoContract AG and a Chairman by PharmaBiome AG.
He received his graduate degree from the University of Basel and a doctorate degree from the University of Basel.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-12-2022 | 14 031 ( 0.11% ) | 152 196 $ | 31-03-2024 |
Actieve functies van Thomas Meier
| Bedrijven | Functie | Begin |
|---|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Founder | 07-09-2004 |
| ONCONETIX, INC. | Director/Board Member | 06-02-2024 |
Novaremed AG
 Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Director/Board Member | 01-05-2020 |
Viopas Venture Consulting GmbH
 Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Corporate Officer/Principal | - |
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Director/Board Member | 01-01-2022 |
Eerdere bekende functies van Thomas Meier
| Bedrijven | Functie | Einde |
|---|---|---|
PharmaBiome AG
 PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Chairman | 01-01-2021 |
| MyoContract AG | Chief Executive Officer | 01-01-2004 |
Opleiding van Thomas Meier
| University of Basel | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SANTHERA PHARMACEUTICALS HOLDING AG | Health Technology |
| ONCONETIX, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
| MyoContract AG | Health Technology |
Novaremed AG
Novaremed AG Pharmaceuticals: MajorHealth Technology Novaremed AG operates as a pharmaceutical company. It develops NEB74S, a molecule for the treatment of chronic pain. The company was founded by Eliahu Kaplan in 2008 and is headquartered in Petah Tikva, Israel. | Health Technology |
PharmaBiome AG
PharmaBiome AG Miscellaneous Commercial ServicesCommercial Services PharmaBiome AG specializes in isolation, characterization, and technology of novel intestinal microbes. It develops and produces microbiome therapies to treat intestinal diseases. The company was founded by Tomas de Wouters and is headquartered in Zurich, Switzerland. | Commercial Services |
Viopas Venture Consulting GmbH
Viopas Venture Consulting GmbH Investment ManagersFinance Viopas Venture Consulting GmbH (Viopas Venture Consulting) is a venture capital firm founded in 2016 by Simon Jules Nebel. The firm is headquartered in Zürich, Switzerland. | Finance |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
